Cosentyx secukinumab logo
Cosentyx® (secukinumab)
Cosentyx secukinumab logo
Rheumatology
Cosentyx® (secukinumab)
Fabhalta iptacopan logo
FABHALTA®▼ (iptacopan)
Ilaris canakinumab logo
Immunology
ILARIS® (canakinumab)
Jakavi ruxolitinib logo
Haematology
JAKAVI® (ruxolitinib)
Kisqali ribociclib logo
Oncology
KISQALI® (ribociclib)
Leqvio inclisiran logo
Cardio-metabolic
LEQVIO®▼ (inclisiran)
Mayzent siponimod logo
Neuroscience
MAYZENT®▼ (siponimod)
SCEMBLIX®▼ (asciminib) logo
Haematology
SCEMBLIX®▼ (asciminib)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.